Secretome Therapeutics has initiated an open label phase 2 study to evaluate the safety and potential skeletal muscle and cardiac effects of STM-01, an investigational cell therapy derived from cardiac progenitor cells.
These cells produce several biological factors that may help regulate inflammation, fibrosis, and tissue repair for DMD.
Read the press release HERE
Letter to the community:
The post Secretome Therapeutics has initiated an open label phase 2 study to evaluate the safety and potential skeletal muscle and cardiac effects appeared first on CureDuchenne.